INS and rheumatoid arthritis: Here, genetic variation in the thiazolidinedione target, which was predicted by the decrement of fasting insulin concentration, was associated with lower risks for RA (OR 0.76 per log-transformed unit of lower fasting insulin, 95%CI 0.63–0.91) and seropositive RA 0.69 (95%CI 0.56–0.85).